We enrolled 58 local advanced BC (LABC) patients received NACT (paclitaxel (PAX) and/or doxorubicin (DOX) -base regimens, plus trastuzumab if HER2 positive), and 24 achieved a pathological complete response (pCR) after NACT. This evidence concerns the gene ERBB2 and breast cancer.